<?xml version='1.0' encoding='utf-8'?>
<document id="23512639"><sentence text="An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults."><entity charOffset="63-90" id="DDI-PubMed.23512639.s1.e0" text="lisdexamfetamine dimesylate" /><entity charOffset="95-106" id="DDI-PubMed.23512639.s1.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.23512639.s1.e0" e2="DDI-PubMed.23512639.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s1.e0" e2="DDI-PubMed.23512639.s1.e1" /></sentence><sentence text="Lisdexamfetamine dimesylate (LDX), a prodrug consisting of d-amphetamine and l-lysine, is being studied in clinical trials of major depressive disorder"><entity charOffset="0-27" id="DDI-PubMed.23512639.s2.e0" text="Lisdexamfetamine dimesylate" /><entity charOffset="29-32" id="DDI-PubMed.23512639.s2.e1" text="LDX" /><entity charOffset="59-72" id="DDI-PubMed.23512639.s2.e2" text="d-amphetamine" /><entity charOffset="77-85" id="DDI-PubMed.23512639.s2.e3" text="l-lysine" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e0" e2="DDI-PubMed.23512639.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e0" e2="DDI-PubMed.23512639.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e0" e2="DDI-PubMed.23512639.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e0" e2="DDI-PubMed.23512639.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e1" e2="DDI-PubMed.23512639.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e1" e2="DDI-PubMed.23512639.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e1" e2="DDI-PubMed.23512639.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e2" e2="DDI-PubMed.23512639.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s2.e2" e2="DDI-PubMed.23512639.s2.e3" /></sentence><sentence text=" Additional drug-drug interaction studies were warranted" /><sentence text="" /><sentence text="This study aimed to describe the pharmacokinetics and safety of LDX and venlafaxine extended-release (VXR), alone or combined"><entity charOffset="72-83" id="DDI-PubMed.23512639.s5.e0" text="venlafaxine" /><entity charOffset="64-74" id="DDI-PubMed.23512639.s5.e1" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s5.e1" e2="DDI-PubMed.23512639.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s5.e1" e2="DDI-PubMed.23512639.s5.e0" /></sentence><sentence text="" /><sentence text="The study was an open-label, two-arm, single-sequence crossover investigation with randomization to treatment sequence" /><sentence text="" /><sentence text="The study was conducted at two clinical study centres and included healthy adult males and females (18-45 years of age)" /><sentence text="" /><sentence text="The study included two single-sequence crossover designs: LDX alone followed by LDX + VXR (Treatment Arm A); and VXR alone followed by VXR + LDX (Treatment Arm B)"><entity charOffset="58-60" id="DDI-PubMed.23512639.s11.e0" text="LDX" /><entity charOffset="80-82" id="DDI-PubMed.23512639.s11.e1" text="LDX" /><entity charOffset="141-143" id="DDI-PubMed.23512639.s11.e2" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s11.e0" e2="DDI-PubMed.23512639.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s11.e0" e2="DDI-PubMed.23512639.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s11.e0" e2="DDI-PubMed.23512639.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s11.e1" e2="DDI-PubMed.23512639.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s11.e1" e2="DDI-PubMed.23512639.s11.e2" /></sentence><sentence text=" Drug treatment was initiated on day 1 with once-daily LDX or VXR alone with 15 days' titration to final dose (LDX 30, 50 and 70 mg for 5 days each; VXR 75, 150 and 225 mg for 5 days each)"><entity charOffset="55-57" id="DDI-PubMed.23512639.s12.e0" text="LDX" /><entity charOffset="111-113" id="DDI-PubMed.23512639.s12.e1" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s12.e0" e2="DDI-PubMed.23512639.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s12.e0" e2="DDI-PubMed.23512639.s12.e1" /></sentence><sentence text=" On days 16-30, VXR, titrated to a final dose of 225 mg, or LDX, titrated to a final dose of 70 mg, was coadministered for participants in Treatment Arm A or B, respectively"><entity charOffset="60-62" id="DDI-PubMed.23512639.s13.e0" text="LDX" /></sentence><sentence text=" On days 31-38, VXR doses were tapered" /><sentence text="" /><sentence text="On days 1-2, 15-16 and 30-31, safety evaluations and blood samples were obtained pre-dose through 24 h post-dose for analysis of LDX, d-amphetamine, venlafaxine (VEN), and O-desmethylvenlafaxine (ODV)"><entity charOffset="134-147" id="DDI-PubMed.23512639.s16.e0" text="d-amphetamine" /><entity charOffset="149-160" id="DDI-PubMed.23512639.s16.e1" text="venlafaxine" /><entity charOffset="162-165" id="DDI-PubMed.23512639.s16.e2" text="VEN" /><entity charOffset="172-194" id="DDI-PubMed.23512639.s16.e3" text="O-desmethylvenlafaxine" /><entity charOffset="129-150" id="DDI-PubMed.23512639.s16.e4" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e4" e2="DDI-PubMed.23512639.s16.e4" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e4" e2="DDI-PubMed.23512639.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e4" e2="DDI-PubMed.23512639.s16.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e4" e2="DDI-PubMed.23512639.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e4" e2="DDI-PubMed.23512639.s16.e3" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e0" e2="DDI-PubMed.23512639.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e0" e2="DDI-PubMed.23512639.s16.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e0" e2="DDI-PubMed.23512639.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e0" e2="DDI-PubMed.23512639.s16.e3" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e1" e2="DDI-PubMed.23512639.s16.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e1" e2="DDI-PubMed.23512639.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e1" e2="DDI-PubMed.23512639.s16.e3" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e2" e2="DDI-PubMed.23512639.s16.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s16.e2" e2="DDI-PubMed.23512639.s16.e3" /></sentence><sentence text=" Combination treatment was considered bioequivalent to single treatment if 90 % confidence intervals (CIs) for geometric mean ratios (GMRs) of analytes fell within the interval 0" /><sentence text="80-1" /><sentence text="25 based on maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration (AUCτ)" /><sentence text=" Safety assessments included treatment-emergent adverse events (TEAEs), pulse rate and blood pressure (BP), clinical laboratory assessments, and 12-lead electrocardiograms (ECG)" /><sentence text="" /><sentence text="Among 80 enrolled subjects, 77 were included in pharmacokinetic and safety analyses" /><sentence text=" Combination LDX + VXR was bioequivalent to LDX alone, based on exposure to d-amphetamine (GMR [95 % CI], Cmax (ng/mL): 0"><entity charOffset="76-89" id="DDI-PubMed.23512639.s23.e0" text="d-amphetamine" /><entity charOffset="13-25" id="DDI-PubMed.23512639.s23.e1" text="LDX" /><entity charOffset="44-56" id="DDI-PubMed.23512639.s23.e2" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s23.e1" e2="DDI-PubMed.23512639.s23.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s23.e1" e2="DDI-PubMed.23512639.s23.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s23.e1" e2="DDI-PubMed.23512639.s23.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s23.e2" e2="DDI-PubMed.23512639.s23.e2" /><pair ddi="false" e1="DDI-PubMed.23512639.s23.e2" e2="DDI-PubMed.23512639.s23.e0" /></sentence><sentence text="97 [0" /><sentence text="82, 1" /><sentence text="14], AUCτ: 0" /><sentence text="95 [0" /><sentence text="81, 1" /><sentence text="12])" /><sentence text=" Exposure to VEN with LDX + VXR (vs"><entity charOffset="22-24" id="DDI-PubMed.23512639.s30.e0" text="LDX" /><entity charOffset="13-15" id="DDI-PubMed.23512639.s30.e1" text="VEN" /><pair ddi="false" e1="DDI-PubMed.23512639.s30.e1" e2="DDI-PubMed.23512639.s30.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s30.e1" e2="DDI-PubMed.23512639.s30.e0" /></sentence><sentence text=" VXR alone) was increased (Cmax: 1" /><sentence text="10 [0" /><sentence text="88, 1" /><sentence text="38], AUCτ: 1" /><sentence text="13 [0" /><sentence text="88, 1" /><sentence text="45]) and ODV decreased (Cmax: 0" /><sentence text="91 [0" /><sentence text="77, 1" /><sentence text="06], AUCτ: 0" /><sentence text="83 [0" /><sentence text="71, 0" /><sentence text="96]), whereas composite VEN + ODV was bioequivalent to VXR alone (Cmax: 0"><entity charOffset="24-26" id="DDI-PubMed.23512639.s43.e0" text="VEN" /></sentence><sentence text="96 [0" /><sentence text="84, 1" /><sentence text="09], AUCτ: 0" /><sentence text="98 [0" /><sentence text="85, 1" /><sentence text="13])" /><sentence text=" TEAEs with LDX or LDX + VXR were similar"><entity charOffset="12-14" id="DDI-PubMed.23512639.s50.e0" text="LDX" /><entity charOffset="19-21" id="DDI-PubMed.23512639.s50.e1" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s50.e0" e2="DDI-PubMed.23512639.s50.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s50.e0" e2="DDI-PubMed.23512639.s50.e1" /></sentence><sentence text=" Maximum mean increases from baseline were: pulse rate, +8" /><sentence text="73 to 12" /><sentence text="76 beats/min with either treatment alone and +17" /><sentence text="67 to 20" /><sentence text="85 beats/min with LDX + VXR; systolic BP, +4"><entity charOffset="18-20" id="DDI-PubMed.23512639.s55.e0" text="LDX" /></sentence><sentence text="32 to 6" /><sentence text="56 mmHg with either treatment alone and +12" /><sentence text="96 to 13" /><sentence text="78 mmHg with LDX + VXR; diastolic BP, +5"><entity charOffset="13-15" id="DDI-PubMed.23512639.s59.e0" text="LDX" /></sentence><sentence text="39 to 5" /><sentence text="74 mmHg with either treatment alone and +12" /><sentence text="09 to 12" /><sentence text="46 mmHg with LDX + VXR"><entity charOffset="13-15" id="DDI-PubMed.23512639.s63.e0" text="LDX" /></sentence><sentence text=" One participant was withdrawn due to a serious TEAE (presyncope)" /><sentence text=" No unexpected, clinically meaningful trends or changes from baseline in mean laboratory or ECG parameters were observed during the trial" /><sentence text="" /><sentence text="In healthy adults, combination LDX + VXR (vs"><entity charOffset="31-33" id="DDI-PubMed.23512639.s67.e0" text="LDX" /></sentence><sentence text=" LDX alone) did not alter exposure to d-amphetamine"><entity charOffset="38-51" id="DDI-PubMed.23512639.s68.e0" text="d-amphetamine" /><entity charOffset="1-13" id="DDI-PubMed.23512639.s68.e1" text="LDX" /><pair ddi="false" e1="DDI-PubMed.23512639.s68.e1" e2="DDI-PubMed.23512639.s68.e1" /><pair ddi="false" e1="DDI-PubMed.23512639.s68.e1" e2="DDI-PubMed.23512639.s68.e0" /></sentence><sentence text=" Although small changes in exposure to VEN (increased) and ODV (decreased) were seen with combination treatment, total VEN + ODV exposure showed no change (vs"><entity charOffset="39-41" id="DDI-PubMed.23512639.s69.e0" text="VEN" /><entity charOffset="119-121" id="DDI-PubMed.23512639.s69.e1" text="VEN" /><pair ddi="false" e1="DDI-PubMed.23512639.s69.e0" e2="DDI-PubMed.23512639.s69.e0" /><pair ddi="false" e1="DDI-PubMed.23512639.s69.e0" e2="DDI-PubMed.23512639.s69.e1" /></sentence><sentence text=" VEN alone)"><entity charOffset="1-3" id="DDI-PubMed.23512639.s70.e0" text="VEN" /></sentence><sentence text=" LDX + VXR led to increases in BP and pulse rate, supporting existing recommendations for vital sign monitoring when using these medications"><entity charOffset="1-3" id="DDI-PubMed.23512639.s71.e0" text="LDX" /></sentence><sentence text="" /></document>